Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk

[1]  Mario Cortina-Borja,et al.  Epistasis in sporadic Alzheimer's disease , 2009, Neurobiology of Aging.

[2]  Xavier Estivill,et al.  Maximizing association statistics over genetic models , 2008, Genetic epidemiology.

[3]  O. Combarros,et al.  Association of genetic variants of ABCA1 with Alzheimer's disease risk , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[4]  T. Montine,et al.  Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease , 2007, Neurology.

[5]  S. DeKosky,et al.  Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease , 2007, Neurobiology of Aging.

[6]  J. Hardy,et al.  ABCA1 polymorphisms and Alzheimer's disease , 2007, Neuroscience Letters.

[7]  M. Franceschi,et al.  The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration , 2007, Neuroscience Letters.

[8]  F. Jessen,et al.  Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. , 2006, International journal of molecular medicine.

[9]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[10]  D. Holtzman,et al.  Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[11]  H. Feldman,et al.  Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.

[12]  F. Pasquier,et al.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  Patrick Browne,et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. , 2005, Archives of neurology.

[14]  O. Combarros,et al.  Consistency in gene-Alzheimer’s disease association studies , 2004, Journal of Epidemiology and Community Health.

[15]  P. Eriksson,et al.  Genotypic Effect of the −565C>T Polymorphism in the ABCA1 Gene Promoter on ABCA1 Expression and Severity of Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  J. Palmgren,et al.  Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β‐amyloid metabolism , 2004, Human mutation.

[18]  Rudolph E. Tanzi,et al.  Alzheimer's disease: the cholesterol connection , 2003, Nature Neuroscience.

[19]  P. Mcgeer,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain , 2001, Neuroreport.

[20]  J. Dietschy,et al.  Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.

[21]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[22]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.